Cognition Therapeutics IncCGTX
What Cognition Therapeutics Inc does.
We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Currently available therapies for these diseases are limited, with many diseases having no approved therapies or treatments. Our goal is to develop disease-modifying treatments for patients with these degenerative disorders.
Our lead product candidate, zervimesine, also known as CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins including β-amyloid, or Aβ and ɑ-synuclein. These and similar protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer’s disease, or AD, and dementia with Lewy bodies, or DLB.
The Company’s initial focus was on the development of zervimesine for the treatment of AD. We believe our evidence demonstrates that zervimesine displaces Aβ oligomers from their neuronal receptors. Based on this mechanism, we believe zervimesine has the potential to slow the loss of synapses and cognitive decline observed in AD. The direct healthcare costs to care for patients with AD and other dementias in the United States is estimated to exceed $350 billion. Approximately 7 million people in the United States have been diagnosed with AD, and the World Health Organization estimates that AD affects as many as 35 million people globally.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$7.8M | -$11.7M | -$21.4M | -$25.8M | -$34.0M | -$23.5M |
| Free cash flow | -$3.4M | -$3.7M | -$18.7M | -$16.2M | -$28.5M | — |
More on CGTX.
- Cognition Therapeutics Inc summary
- Cognition Therapeutics Inc financial statements
- Cognition Therapeutics Inc key metrics
- Cognition Therapeutics Inc health scores and style box
- Cognition Therapeutics Inc earnings
- Cognition Therapeutics Inc dividends
- Cognition Therapeutics Inc valuation
- Cognition Therapeutics Inc ownership and insiders
- Cognition Therapeutics Inc peers
Figures from Cognition Therapeutics Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.